Corixa (company)

Corixa was a biotechnology/pharmaceutical company based in Seattle, Washington involved in the development of immunotherapeutics to combat autoimmune diseases, infectious diseases, and cancer. It was founded in 1994. It operated a laboratory and production facility in Hamilton, Montana.

Corixa
Typebiotechnology/pharmaceutical
Successoracquired by GlaxoSmithKline
Founded1994 in Seattle, Washington
DefunctMarch 31, 2006 (2006-03-31)
Headquarters
Seattle
,
Washington
Number of locations
2
ParentGlaxoSmithKline (United States) 

The name Corixa comes from the true bug (Insecta: Hemiptera: Heteroptera) genus Corixa (family Corixidae, Water boatman), described by Geoffroy, in 1762.

On 12 July 2005, the European pharmaceuticals giant GlaxoSmithKline completed the acquisition of Corixa.[1] GSK had formerly made use of the Corixa's MPL (Monophosphoryl lipid A, a derivative of the lipid A molecule), an adjuvant in some of their vaccines.

On 31 March 2006, Corixa's doors closed after over 11 years in business.

  • "Corixa Corporation - powering the immune system". Archived from the original on 2006-03-01.

References

  1. "Glaxo to acquire Corixa for $300 million". Market Watch. April 29, 2005.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.